Integrated peripheral boost in preoperative radiotherapy for the locally most advanced non-resectable rectal cancer patients

References

• Hughes R, Harrison M, Glynne-Jones R. Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy? Acta Oncol 2010;49:378–81.
   PubMed Web of Science ®Google Scholar
• Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, . Multidisciplinary rectal cancer management. Radiother Oncol 2009;92:148–63.
   PubMed Web of Science ®Google Scholar
• Valentini V, Glimelius B. Rectal cancer radiotherapy: Towards European consensus. Acta Oncol 2010;49:1206–16.
   PubMed Web of Science ®Google Scholar
• Blomqvist L, Glimelius B. The ‘good’, the ‘bad’, and the ‘ugly’ rectal cancers. Acta Oncol 2008;47:5–8.
   PubMed Web of Science ®Google Scholar
• Bjerkeset T, Morild I, Mork S, Soreide O. Tumor characteristics in colorectal cancer and their relationship to treatment and prognosis. Dis Colon Rectum 1987;30:934–8.
   PubMed Web of Science ®Google Scholar
• Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Pahlman L, . Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008;26:3687–94.
   PubMed Web of Science ®Google Scholar
• Mohiuddin M, Regine WF, John WJ, Hagihara PF, McGrath PC, Kenady DE, . Preoperative chemoradiation in fixed distal rectal cancer: Dose time factors for pathological complete response. Int J Radiat Oncol Biol Phys 2000; 46:883–8.
   PubMed Web of Science ®Google Scholar
• Steele GD, Jr., Herndon JE, Bleday R, Russell A, Benson A, 3rd, Hussain M, . Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol 1999;6:433–41.
   PubMed Web of Science ®Google Scholar
• Russell AH, Harris J, Rosenberg PJ, Sause WT, Fisher BJ, Hoffman JP, . Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: Long-term results of Radiation Therapy Oncology Group protocol 89-02. Int J Radiat Oncol Biol Phys 2000;46:313–22.
   PubMed Web of Science ®Google Scholar
• Jingu K, Ariga H, Kaneta T, Takai Y, Takeda K, Katja L, . Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: A planning study with comparison of DVH and NTCP. BMC Cancer 2010;10:127.
   PubMed Web of Science ®Google Scholar
• Caravatta L, Picardi V, Tambaro R, Padula GD, Macchia G, Deodato F, . Neoadjuvant accelerated concomitant boost radiotherapy and multidrug chemotherapy in locally advanced rectal cancer: A dose-escalation study. Am J Clin Oncol Epub2011 May 6.
   Google Scholar
• Duthoy W, De Gersem W, Vergote K, Boterberg T, Derie C, Smeets P, . Clinical implementation of intensity-modulated arc therapy (IMAT) for rectal cancer. Int J Radiat Oncol Biol Phys 2004;60:794–806.
   PubMed Web of Science ®Google Scholar
• De Ridder M, Tournel K, Van Nieuwenhove Y, Engels B, Hoorens A, Everaert H, . Phase II study of preoperative helical tomotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2008;70:728–34.
   PubMed Web of Science ®Google Scholar
• Engels B, De Ridder M, Tournel K, Sermeus A, De Coninck P, Verellen D, . Preoperative helical tomotherapy and megavoltage computed tomography for rectal cancer: Impact on the irradiated volume of small bowel. Int J Radiat Oncol Biol Phys 2009;74:1476–80.
   PubMed Web of Science ®Google Scholar
• Braendengen M, Hansson K, Radu C, Siegbahn A, Jacobsson H, Glimelius B. Delineation of gross tumor volume (GTV) for radiation treatment planning of locally advanced rectal cancer using information from MRI or FDG-PET/CT: A prospective study. Int J Radiat Oncol Biol Phys 2011;81:e439–45.
   PubMed Web of Science ®Google Scholar
• Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, . Elective clinical target volumes for conformal therapy in anorectal cancer: A radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009;74:824–30.
   PubMed Web of Science ®Google Scholar
• Sanguineti G, Little M, Endres EJ, Sormani MP, Parker BC. Comparison of three strategies to delineate the bowel for whole pelvis IMRT of prostate cancer. Radiother Oncol 2008;88:95–101.
   PubMed Web of Science ®Google Scholar
• Fiorino C, Alongi F, Perna L, Broggi S, Cattaneo GM, Cozzarini C, . Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 2009;75:29–35.
   PubMed Web of Science ®Google Scholar
• RaySearch. RayStation planning system. Stockholm, Sweden: RaySearch Laboratories AB; 2012.
   Google Scholar
• Martínez-Monge R, Nag S, Martin EW. Three different intraoperative radiation modalities (electron beam, high-dose-rate brachytherapy, and iodine-125 brachytherapy) in the adjuvant treatment of patients with recurrent colorectal adenocarcinoma. Cancer 1999;86:236–47.
   PubMed Web of Science ®Google Scholar
• Wilking N. Intraoperative radiotherapy (IORT) – A critical review of the literature. Acta Oncol 2003;42:384–5.
   Google Scholar
• Tatsuzaki H, Urie MM, Willett CG. 3-D comparative study of proton vs. x-ray radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 1992;22:369–74.
   PubMed Web of Science ®Google Scholar
• Isacsson U, Montelius A, Jung B, Glimelius B. Comparative treatment planning between proton and X-ray therapy in locally advanced rectal cancer. Radiother Oncol 1996;41: 263–72.
   PubMed Web of Science ®Google Scholar
• Johansson J. Comparative treatment planning in radiotherapy and clinical impact of proton relative biological effectiveness [Doctoral thesis]. Uppsala: Uppsala University; 2006.
   Google Scholar
• Wolff HA, Wagner DM, Conradi LC, Hennies S, Ghadimi M, Hess CF, . Irradiation with protons for the individualized treatment of patients with locally advanced rectal cancer: A planning study with clinical implications. Radiother Oncol 2012;102:30–7.
   PubMed Web of Science ®Google Scholar
• Tilly N, Johansson J, Isacsson U, Medin J, Blomquist E, Grusell E, . The influence of RBE variations in a clinical proton treatment plan for a hypopharynx cancer. Phys Med Biol 2005;50:2765–77.
   PubMed Web of Science ®Google Scholar
• Baglan KL, Frazier RC, Yan D, Huang RR, Martinez AA, Robertson JM. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2002;52:176–83.
   PubMed Web of Science ®Google Scholar
• Tho LM, Glegg M, Paterson J, Yap C, MacLeod A, McCabe M, . Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: Investigating dose-volume relationships and role for inverse planning. Int J Radiat Oncol Biol Phys 2006;66:505–13.
   PubMed Web of Science ®Google Scholar
• Robertson JM, Lockman D, Yan D, Wallace M. The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2008;70:413–8.
   PubMed Web of Science ®Google Scholar
• Roeske JC, Bonta D, Mell LK, Lujan AE, Mundt AJ. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol 2003;69:201–7.
   PubMed Web of Science ®Google Scholar
• Kavanagh BD, Pan CC, Dawson LA, Das SK, Li XA, Ten Haken RK, . Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S101–7.
   Google Scholar
• DeLaney TF, Liebsch NJ, Pedlow FX, Adams J, Dean S, Yeap BY, . Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 2009;74:732–9.
   PubMed Web of Science ®Google Scholar
• Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, . Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355: 1114–23.
   PubMed Web of Science ®Google Scholar
• Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, . Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: Results of FFCD 9203. J Clin Oncol 2006;24: 4620–5.
   PubMed Web of Science ®Google Scholar